- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01820780
Early Care After Discharge of HF Patients (ECAD-HF)
Usefulness of a Short-time But Very Early Specialized Follow-up After Hospitalization for Acute Heart Failure: a Randomized Controlled Trial.
After decompensated heart failure, a number of patients have high risk of early rehospitalization as well as death. Specialized medical management for a short period but very early after discharge could be critical for optimizing care and improving early outcome.
This study aims to compare such early intensive medical management with usual care in high-risk patients after discharge.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
At discharge, high-risk HF patients are selected and randomized in two groups:
- Control group: usual disease management according to guidelines and including first medical consultation and biological test within the 4-week time following discharge.
- Active group: consultations with HF specialist including biological test at weeks 1, 2 and 4 are planned in addition to usual management.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Paris, Frankrike, 75010
- Service de Cardiologie - Hôpital Lariboisière
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- 18 years or more
- consent signed
Acute or decompensated heart failure with one or more of following criteria::
- Discharge BNP > 350 pg/ml or NTproBNP > 2200 pg/ml
- Discharge serum creatinine ≥ 180µM
- Discharge systolic blood pressure ≤ 110mmHg
- Previous hospitalisation for acute heart failure < 6 months
Exclusion Criteria:
- acute coronary syndrome,
- acute myocarditis,
- isolated right HF,
- transient HF,
- planned cardiac surgery,
- high risk of short-term non-cardiac death,
- planned management within rehabilitation center/HF clinic at discharge
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: intensive disease management
Planned consultations with HF specialist including biological test at weeks 1, 2 and 4; in addition to usual care.
|
Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
|
|
Aktiv komparator: usual disease management
usual care according to guidelines; including first medical consultation and biological test within the 4-week time following discharge.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Number of participants with all cause death or unplanned hospitalization at 6 months
Tidsram: 6 months
|
6 months
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
All cause mortality at 12 months
Tidsram: one year
|
one year
|
|
Unplanned HF-related hospitalization at 6 and 12 months
Tidsram: 6 and 12 months
|
6 and 12 months
|
|
Number of alive and hospitalization-free days at 6 and 12 months
Tidsram: 6 and 12 months
|
6 and 12 months
|
|
Mean and distribution modified Goldman classe at 6 months
Tidsram: 6 months
|
6 months
|
|
Natriuretic peptides blood levels at 6 months.
Tidsram: 6 months.
|
6 months.
|
|
Global cost of patient management
Tidsram: from day0 to 12 months
|
from day0 to 12 months
|
|
HF-treatment at 6 months
Tidsram: 6 months
|
6 months
|
|
Mean and distribution NYHA classe at 6 months
Tidsram: 6 months
|
6 months
|
|
Analysis of subgroups (LVEF altered or not, first HF episode or not, age> or ≤ 75, Changes in levels of BNP or NT-proBNP between day0 and the second consultation in the active group: ≥ 30% decrease, ≥ 30% increase, Intermediate variation).
Tidsram: 6 months
|
6 months
|
|
Biomarkers measured in plasma collected at day0: predictive value of the risk of death and hospitalization during the period of 6 months
Tidsram: 6 months
|
6 months
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: LOGEART Damien, MD, PhD, Lariboisière Hospital, APHP
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- P110128
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .